2. Academic Validation
  3. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection

Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection

  • J Am Coll Cardiol. 2012 May 29;59(22):1921-7. doi: 10.1016/j.jacc.2011.09.086.
Rakesh C Kukreja 1,  Fadi N Salloum,  Anindita Das
Affiliations

Affiliation

  • 1 Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia 23298, USA. [email protected]
PMID: 22624832 DOI: 10.1016/j.jacc.2011.09.086
Abstract

Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase (PDE)-5 inhibitors and Guanylate Cyclase activators may represent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative therapeutic agents for enhancing the chemosensitivity of doxorubicin while providing concurrent cardiac benefit.

Figures